Digoxin for relapsed non-WNT non-SHH medulloblastoma
Treatments studied
Part of Cancer clinical trials.
This trial tests whether the drug digoxin can help treat medulloblastoma that has come back after standard treatments like chemotherapy and radiation. Digoxin is a heart medicine being studied for its anticancer effects against a specific type of medulloblastoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are older than 12 months but younger than 30 years old.
- Your medulloblastoma has come back (relapsed) and is a specific subtype called non-WNT, non-SHH.
- You have received at least one round of chemotherapy and radiation therapy in the past.
- You have measurable tumor on an MRI scan (at least a certain size).
- You do not have certain heart conditions or take medications that interfere with digoxin.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding arsenic trioxide to standard chemotherapy can help children whose medulloblastoma has come back or is hard to treat, especially if the tumor has certain genetic changes. The goal is to see if this combination can shrink tumors or slow their growth.
This trial tests whether adding a thyroid hormone (liothyronine) to a standard chemotherapy combination (bevacizumab, irinotecan, temozolomide) can help children and young adults with medulloblastoma that has come back after initial treatment.
This Phase 2 study tests DFMO (a maintenance medicine) to help stop medulloblastoma from coming back or worsening after prior treatment. It focuses on children and young people with specific high-risk tumor types or tumors that have returned or not responded well to treatment.
This trial tests a new medicine (RVU120) combined with an existing drug (everolimus) in children whose medulloblastoma (a type of brain tumor) has come back or gotten worse. The goal is to see if this combination can help stop the tumor from growing.
This trial tests two drugs, axitinib and etoposide, taken by mouth to treat children and young adults with medulloblastoma or ependymoma that has returned or not responded to standard treatment. The goal is to see if this combination can shrink tumors or slow their growth.
This study tests a personalized treatment plan for children and young adults whose medulloblastoma or ependymoma has come back. It aims to guide doctors using new tissue from surgery or biopsy after earlier treatments are fully finished.
Hear when a new Medulloblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.